Comparative Pharmacology
Head-to-head clinical analysis: INFANT S ADVIL versus NAPROXEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INFANT S ADVIL versus NAPROXEN SODIUM.
INFANT'S ADVIL vs NAPROXEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
200-400 mg orally every 4-6 hours as needed; maximum daily dose 1200 mg.
220-550 mg orally twice daily; maximum 1375 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 to 2 hours in infants and children, which is shorter than in adults (2-4 hours). This shorter half-life reflects higher clearance in pediatric populations and has clinical implications for dosing frequency (typically every 6-8 hours).
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Renal excretion of metabolites (primarily glucuronide and sulfate conjugates of ibuprofen) accounts for approximately 90% of elimination, with less than 10% excreted unchanged in urine. Biliary/fecal excretion is minimal (<5%).
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Category C
Category D/X
NSAID
NSAID